DR MARY VINSON

Preclinical and Clinical Development

Mary Vinson is a senior biotechnology leader and consultant with over 25 years of experience in the pharmaceutical and biotech industries. Her expertise spans drug discovery through to clinical proof of concept, with a focus on the transition from pre-clinical into early clinical trials. She has experience in a range of therapeutic areas and has developed small molecules, antibodies, and cell and gene therapies. 
Mary has held leadership roles in both large pharmaceutical companies and emerging biotechs, most recently bit.bio and Autolus where she built and led cross-functional teams, shaped development and regulatory strategies, and delivered programs involving scientifically complex products and novel technologies that advanced pipelines and supported investor engagement. 
Earlier roles at Heptares, Cantab, and Proximagen involved leading small molecule programs in neurology and infectious diseases, overseeing preclinical development, regulatory submissions, and outsourced clinical trials. Mary began her career at GSK, progressing from bench scientist to program lead for antibody and small molecule therapies in neurology.
Mary has a degree in molecular biology from the University of Manchester and a DPhil in cell biology from Oxford University.